Understanding the Legal Risks of BPC 157 and Other Unapproved Peptides Holt Law FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The FDA's Ban of Therapeutic Peptides: A Threat to Health Freedom Slim 'n Sleek